One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

As part of our investigation into emissions of ethylene oxide, Grist created an informational guide so you can learn more about what this toxic gas is and how you may be at risk.